*You need to join by phone if you want to ask Dr. Stein your questions.*
IDH mutations are found in approximately 20% of adults with AML. Both IDH1 and IDH2 mutations are typically found in older AML patients and have an intermediate risk profile, with IDH2 being the more common of the two. Targeted therapy drugs, called IDH inhibitors have been developed to address these mutations.
Ivosidenib (Tibsovo) and enasidinib (Idhifa) are IDH inhibitors and were approved for use in relapsed/refractory AML with IDH1 and IDH2 mutations, respectively. Clinical trials have been exploring the use of different combinations with other drugs such as azacitidine and venetoclax to improve their effectiveness.
Ivosidenib (Tibsovo) was just recently approved by the FDA in May 2022 for use in combination with azacitidine for newly diagnosed patients age 75 years or older and those not able to do intensive chemotherapy.
In this podcast episode, Dr. Eytan Stein will discuss IDH mutations, the current treatment options, as well as the recent FDA approval of ivosidenib (Tibsovo) and what that means for today's treament landscape.
Thank you to our episode sponsor, Bristol Myers Squibb.
Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.
Hematologist Oncologist, Director of the Program for Drug Development in Leukemia at MSKCC
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.